Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Article 2022 en
Authors
MG
Mrinal M. Gounder
AR
Albiruni Abdul Razak
NS
Neeta Somaiah
Abstract
1 min read
Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of <i>CALB1</i> expression as a predictive biomarker for selinexor in DD-LPS is warranted.
Leopoldo Villegas, Rose McGready, Mg Htway, Moo Kho Paw, Mupawjay Pimanpanarak, Ratree Arunjerdja, Samuel Jacher Viladpai‐nguen, Brian Greenwood, Sir Nicholas White, François Nosten
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Éric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto,
Discussion(0)
No comments yet. Be the first to comment.